Von Hippel-Lindau tumor suppressor: Not only HIF's executioner

Trends in Molecular Medicine

Volumn 10, Issue 4, 2004, Pages 146-149

  Czyzyk Krzeska, Maria F ^a   Meller, Jaroslaw ^b,c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; HEAT SHOCK PROTEIN 70; HYPOXIA INDUCIBLE FACTOR 1; RNA POLYMERASE II; TRANSCRIPTION FACTOR; UBIQUITIN; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ANGIOGENESIS; ANGIOMA; AUTOSOMAL DOMINANT DISORDER; CENTRAL NERVOUS SYSTEM; CHROMOSOME 3P; CLINICAL FEATURE; CRYSTALLOGRAPHY; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HEMANGIOBLASTOMA; HUMAN; HYDROXYLATION; HYPOXIA; KIDNEY CARCINOMA; PHENOTYPE; PHEOCHROMOCYTOMA; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; RETINA DISEASE; REVIEW; TRANSACTIVATION; UBIQUITINATION; ULTRAVIOLET C RADIATION; VASCULAR TUMOR; VON HIPPEL LINDAU DISEASE;

EID: 1642603441     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2004.02.004     Document Type: Short Survey

References (34)

1. Ang S.O., et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat. Genet. 32:2002;614-621.
2. Cockman M., et al. Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275:2000;25733-25741.
3. Kaelin W.J. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer. 2:2002;673-682.
4. Duan D.R., et al. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science. 269:1995;1402-1406.
5. Feldman D.E., et al. Formation of the VHL-Elongin BC tumor suppressor complex is mediated by the chaperonin TRiC. Mol. Cell. 4:1999;1051-1061.
6. Hansen W.J., et al. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity. Mol. Cell. Biol. 22:2002;1947-1960.
7. Melville M.W., et al. The Hsp70 and Tric/CCT chaperone system cooperate in vivo to assemble the VHL tumor suppressor complex. Mol. Cell. Biol. 23:2003;3141-3152.
8. Ohh M., et al. An intact NEDD8 pathway is required for cullin-dependent ubiquitylation in mammalian cells. EMBO Rep. 3:2002;177-182.
9. Stebbins C.E., et al. Structure of the VHL-elongin C-elongin B complex: implications for VHL tumour suppressor function. Science. 284:1999;455-461.
10. Hon W.C., et al. Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL. Nature. 417:2002;975-977.
11. Ohh M., et al. Ubiquitination of HIF requires direct binding to the von Hippel- Lindau protein β-domain. Nat. Cell Biol. 2:2000;423-427.
12. Ivan M., et al. HIF-α targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 292:2001;464-468.
13. 2-regulated prolyl hydroxylation. Science. 292:2001;468-472.
14. Epstein A.C., et al. C. Elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 107:2001;43-54.
15. Corn P.G., et al. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein. Nat. Genet. 35:2003;229-237.
16. Ferrell K., et al. Regulatory subunit interactions of the 26S proteasome, a complex problem. Trends Biochem. Sci. 25:2000;83-88.
17. Nelbock P., et al. A cDNA for a protein that interacts with the human immunodeficiency virus Tat transactivator. Science. 248:1990;1650-1653.
18. DeMartino G.N., et al. Identification, purification and characterization of a PA700-dependent activator of the proteasome. J. Biol. Chem. 271:1996;3112-3118.
19. Barillari G., Ensloi B. Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi Sarcoma. Clin. Microbiol. Rev. 15:2002;310-326.
20. Na X., et al. Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein. EMBO J. 22:2003;4249-4259.
21. Kuznetsova A.V., et al. Von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination. Proc. Natl. Acad. Sci. U. S. A. 100:2003;2706-2711.
22. Schoenfeld A.R., et al. The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis. Oncogene. 19:2000;5851-5857.
23. Li Z., et al. Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 277:2002;4656-4662.
24. Okuda H., et al. The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C. J. Biol. Chem. 276:2001;43611-43617.
25. Hergovich A., et al. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat. Cell Biol. 5:2003;64-70.
26. Ohh M., et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell. 1:1998;959-968.
27. Hoffman M.A., et al. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum. Mol. Genet. 10:2001;1019-1027.
28. Kamura T., et al. MUF1, a novel elongin BC-interacting leucine-rich repeat protein that can assemble with Cul5 and Rbx1 to reconstitute a ubiquitin ligase. J. Biol. Chem. 276:2001;29748-29753.
29. Kroll S.L., et al. Von Hippel-Lindau protein induces hypoxia-regulated arrest of tyrosine hydroxylase transcript elongation in pheochromocytoma cells. J. Biol. Chem. 274:1999;30109-30114.
30. Bauer L.B., et al. Endogenous rat von Hippel-Lindau tumor suppressor protein regulates catecholaminergic phenotype in PC12 cells. Cancer Res. 62:2002;1682-1687.
31. Li Z., et al. The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1a transcriptional activity. EMBO J. 22:2003;1857-1867.
32. Lee C., et al. Structure of human FIH-1 reveals a unique active site pocket and interaction sites for HIF-1 and VHL. J. Biol. Chem. 278:2003;7558-7563.
33. Cohen H.T., et al. An important VHL tumor suppressor domain mediates Sp1-binding and self-association. Biochem. Biophys. Res. Commun. 266:1999;43-50.
34. Sayle R.A., Milner-White E.J. RASMOL: biomolecular graphics for all. Trends Biochem. Sci. 20:1995;374-376.